Douglas Ingram, president and chief government officer of Sarepta Therapeutics Inc., through the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023.
Michael Nagle | Bloomberg | Getty Photographs
Shares of Sarepta Therapeutics plunged greater than 30% on Friday as the way forward for its accredited gene remedy therapy appeared in danger.
The Meals and Drug Administration will request that the corporate voluntarily cease all shipments of the therapy, Elevidys, an individual conversant in the matter advised CNBC.
Individually, FDA Commissioner Marty Makary told Bloomberg News the company is contemplating whether or not the corporate’s gene remedy ought to keep available on the market.
The FDA has been investigating two affected person deaths tied to Elevidys. The corporate additionally reported a 3rd demise tied to a separate experimental gene remedy.
Sarepta didn’t instantly reply to a request for remark.
This story is creating. Please examine again for updates.